Milbury Max A. 4
4 · ProMIS Neurosciences Inc. · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
ProMIS (PMN) Principal Accounting Officer Max Milbury Acquires 6,595 Shares
What Happened
Max A. Milbury, Principal Accounting Officer of ProMIS Neurosciences (PMN), acquired 6,595 common shares on February 3, 2026 at $12.13 per share for a total cash outlay of $79,997. He also received Common Share Warrants exercisable for 6,595 shares (recorded as a derivative acquisition). The purchases were made under a Securities Purchase Agreement with selected investors.
Key Details
- Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely within required reporting window).
- Share purchase: 6,595 common shares at $12.13 each = $79,997.
- Derivative: Common Share Warrants to purchase 6,595 shares (warrant entry reported as N/A for price/value on the Form 4).
- Post-transaction beneficial ownership: not specified on this filing.
- Notable footnotes: (F1) Shares and warrants acquired under a Securities Purchase Agreement; (F2) figures reflect a 1-for-25 reverse split effective Nov 28, 2025; (F3) warrants expire on the earlier of Feb 3, 2031 or within 60 days after a public announcement of topline single-ascending-dose PMN310 cohort data.
Context
This was a direct purchase in a private placement (not an open-market sale). The addition of warrants means Milbury can buy the same number of shares later under specified terms and expiration triggers tied to clinical data timing. Purchases by insiders are often watched by investors as a stronger signal than routine sales, but this summary is factual and does not infer motive.
Insider Transaction Report
- Award
Common Shares
[F1][F2]2026-02-03$12.13/sh+6,595$79,997→ 8,409 total - Award
Warrants to purchase Common Shares
[F1][F3]2026-02-03+6,595→ 6,595 totalExercise: $14.40From: 2026-02-03Exp: 2031-02-03→ Common Shares (6,595 underlying)
Footnotes (3)
- [F1]On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
- [F2]Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
- [F3]The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.